The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.

The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.

Date of Patent:
Dec. 25, 2018

Filed:

Nov. 11, 2015
Applicants:

Tokyo Metropolitan Institute of Medical Science, Tokyo, JP;

National Institutes of Biomedical Innovation, Health and Nutrition, Osaka, JP;

The Chemo-sero-therapeutic Research Institute, Kumamoto, JP;

Inventors:

Michinori Kohara, Tokyo, JP;

Yasuhiro Yasutomi, Ibaraki, JP;

Yumiko Shiogama, Ibaraki, JP;

Attorney:
Primary Examiner:
Int. Cl.
CPC ...
A61K 39/00 (2006.01); A61K 39/12 (2006.01); A61K 39/275 (2006.01); A01N 63/00 (2006.01); A61K 48/00 (2006.01); C12N 15/863 (2006.01); A61K 39/29 (2006.01); A61K 31/7088 (2006.01); A61K 35/76 (2015.01); C12N 15/09 (2006.01); G01N 33/576 (2006.01); C07H 21/00 (2006.01);
U.S. Cl.
CPC ...
C12N 15/8636 (2013.01); A61K 31/7088 (2013.01); A61K 35/76 (2013.01); A61K 39/29 (2013.01); C12N 15/09 (2013.01); G01N 33/5767 (2013.01); A61K 48/00 (2013.01); C07H 21/00 (2013.01);
Abstract

The present invention can induce stronger cellular immunity to hepatitis C and provide a treatment means and a prevention means that are effective in completely eliminating the hepatitis C virus (HCV). Provided is a pharmaceutical composition for the treatment and/or prevention of hepatitis C, said composition comprising a recombinant vaccinia virus (a) and a recombinant vector (b) and characterized in that after one of the recombinant vaccinia virus (a) and the recombinant vector (b) is administered for initial immunity, the other is administered for additional immunity. The recombinant vaccinia virus (a) contains an expression promoter and all or a portion of the cDNA of the HCV genome. The recombinant vector (b) contains an expression promoter and all or a portion of the cDNA of the HCV (where the cDNA contained in the recombinant vector (b) has a different base sequence than that included in the recombinant vaccinia virus (a)).


Find Patent Forward Citations

Loading…